Legislation and Legislative Advocacy
The American Hospital Association (AHA) shares resources on health care legislation being considered by the U.S. House and Senate and legislative advocacy opportunities for hospitals and health systems.
AHA letter to Representatives Crowley and Costello expressing support for H.R. 5818, the Opioid Workforce Treatment Act of 2018.
Health care is changing as the march from volume to value moves forward. And hospitals and health systems are redefining the “H” to meet the demands of the moment, and of the future, in a way that is even more responsive to our patients and communities.
The House Energy and Commerce Committee yesterday approved 32 bills to address the opioid crisis, including 12 AHA-supported bills.
House Speaker Paul Ryan (R-WI) yesterday discussed a potential compromise on the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974/H.R. 2212), as part of congressional action to address high drug prices.
The House Energy and Commerce Committee today approved more than 20 bills to address the opioid crisis.
The House of Representatives last night voted 347-70 to approve bipartisan legislation to streamline and consolidate the Department of Veterans Affairs’ community care programs into a permanent Veterans Community Care Program.
The AHA and seven other national hospital organizations yesterday voiced strong support for legislation that would allow states to receive federal matching funds for services provided to a Medicaid beneficiary with a substance use disorder in an Institution for Mental Disease.
Sens. Mike Lee (R-UT), Orrin Hatch (R-UT), Thom Tillis (R-NC) and Charles Grassley (R-IA) yesterday introduced the Standard Merger and Acquisition Reviews Through Equal Rules Act (S. 2847), AHA-supported legislation that would standardize the merger review process for the two federal antitrust…
AHA letter to the Senate expressing support for S. 2847, the Standard Merger and Acquisition Reviews Through Equal Rules Act of 2018, also known as the SMARTER Act.
The Food and Drug Administration Friday issued final guidance clarifying that an organization may operate both a compounding pharmacy and outsourcing facility at the same address or general location if they are completely segregated by clearly identified boundaries.